Osama Altayar

Dr. Osama Altayar

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Gastroenterology
Verified
Journal Article
Open access
PDF file
SSShahnaz Sultan
Shahnaz Sultan
OAOsama Altayar
Osama Altayar
SSShazia M. Siddique
Shazia M. Siddique
PDPerica Davitkov
Perica Davitkov
JFJoseph D. Feuerstein
Joseph D. Feuerstein
HEHashem B. El-Serag
Hashem B. El-Serag
Background & Aims Multiple gastrointestinal (GI) symptoms, including diarrhea, nausea/vomiting, and abdominal pain, as well as liver enzyme abnormalities, have been variably reported in patients with coronavirus disease 2019 (COVID-19). This document provides best practice statements and recommendations for consultative management based on a systematic review and meta-analysis of international data on GI and liver manifestations of COVID-19. Methods We performed a systematic literature search to identify published and unpublished studies using OVID Medline and preprint servers (medRxiv, LitCovid, and SSRN) up until April 5, 2020; major journal sites were monitored for US publications until April 19, 2020. We pooled the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. Results We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) and alanine transaminase 15.0% (95% CI, 13.6%–16.4%). When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%–20.1%). Isolated GI symptoms were reported rarely. We also summarized the Gl and liver adverse effects of the most commonly utilized medications for COVID-19. Conclusions GI symptoms are associated with COVID-19 in <10% of patients. In studies outside of China, estimates are higher. Further studies are needed with standardized GI symptoms questionnaires and liver function test checks on admission to better quantify and qualify the association of these symptoms with COVID-19. Based on findings from our meta-analysis, we provide several Best Practice Statements for the consultative management of COVID-19.

1 February 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
JDJuan Pablo Domecq
Juan Pablo Domecq
GPGabriela Prutsky
Gabriela Prutsky
ALAaron Leppin
Aaron Leppin
MSMohamad Sonbol
Mohamad Sonbol
OAOsama Altayar
Osama Altayar
MMMohammad Hassan Murad
Mohammad Hassan Murad
Various drugs affect body weight as a side effect. We conducted this systematic review and meta-analysis to summarize the evidence about commonly prescribed drugs and their association with weight change. MEDLINE, DARE, and the Cochrane Database of Systematic Reviews were searched to identify published systematic reviews as a source for trials. We included randomized trials that compared an a priori selected list of drugs to placebo and measured weight change. We extracted data in duplicate and assessed the methodological quality using the Cochrane risk of bias tool. We included 257 randomized trials (54 different drugs; 84 696 patients enrolled). Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperidone (0.8 kg), gabapentin (2.2 kg), tolbutamide (2.8 kg), pioglitazone (2.6 kg), glimepiride (2.1 kg), gliclazide (1.8 kg), glyburide (2.6 kg), glipizide (2.2 kg), sitagliptin (0.55 kg), and nateglinide (0.3 kg). Weight loss was associated with the use of metformin (1.1 kg), acarbose (0.4 kg), miglitol (0.7 kg), pramlintide (2.3 kg), liraglutide (1.7 kg), exenatide (1.2 kg), zonisamide (7.7 kg), topiramate (3.8 kg), bupropion (1.3 kg), and fluoxetine (1.3 kg). For many other remaining drugs (including antihypertensives and antihistamines), the weight change was either statistically nonsignificant or supported by very low-quality evidence. Several drugs are associated with weight change of varying magnitude. Data are provided to guide the choice of drug when several options exist and institute preemptive weight loss strategies when obesogenic drugs are prescribed.

6 December 2019 in Gastroenterology
Verified
Journal Article
Closed access
SGSamir Gupta
Samir Gupta
DLDan Li
Dan Li
HSHashem B. El Serag
Hashem B. El Serag
PDPerica Davitkov
Perica Davitkov
OAOsama Altayar
Osama Altayar
RMReem A. Mustafa
Reem A. Mustafa

1 August 2020 in Gastroenterology
Verified
Journal Article
Open access
PDF file
SSShahnaz Sultan
Shahnaz Sultan
JLJoseph K. Lim
Joseph K. Lim
OAOsama Altayar
Osama Altayar
PDPerica Davitkov
Perica Davitkov
JFJoseph D. Feuerstein
Joseph D. Feuerstein
HEHashem B. El-Serag
Hashem B. El-Serag
Multiple questions have been raised regarding the GI and liver manifestations of COVID-19 infection and the implications of SARS-CoV-2 infection on GI endoscopy. A joint society statement by the American Gastroenterological Association (AGA), the American Association for the Study of Liver Diseases, the American College of Gastroenterology, and the American Society for Gastrointestinal Endoscopy on March 15, 2020 highlighted the potential for SARS-CoV-2 transmission through droplets, an established mode of transmission, and possibly fecal shedding, and the associated risk for transmission to endoscopy personnel during GI endoscopy procedures. American Gastroenterological Association Joint GI Society Message: COVID-19 clinical insights for our community of gastroenterologists and gastroenterology care providers. https://www.gastro.org/press-release/joint-gi-society-message-covid-19-clinical-insights-for-our-community-of-gastroenterologists-and-gastroenterology-care-providers Date accessed: March 21, 2020 Google Scholar

1 August 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
SPSamir H. Patel
Samir H. Patel
ZWZhen Wang
Zhen Wang
WWWilliam W Wong
William W Wong
MMMohammad Hassan Murad
Mohammad Hassan Murad
CBCourtney R Buckey
Courtney R Buckey
RFRobert L Foote
Robert L Foote

1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MFMazen Ferwana
Mazen Ferwana
IAImad Abdulmajeed
Imad Abdulmajeed
AAAli Alhajiahmed
Ali Alhajiahmed
WMWedad Madani
Wedad Madani
BFBelal Firwana
Belal Firwana
BKBandar Knawy
Bandar Knawy
AIM: To quantitatively summarize and appraise the available evidence of urea breath test (UBT) use to diagnose Helicobacter pylori (H. pylori) infection in patients with dyspepsia and provide pooled diagnostic accuracy measures. METHODS: We searched MEDLINE, EMBASE, Cochrane library and other databases for studies addressing the value of UBT in the diagnosis of H. pylori infection. We included cross-sectional studies that evaluated the diagnostic accuracy of UBT in adult patients with dyspeptic symptoms. Risk of bias was assessed using QUADAS (Quality Assessment of Diagnostic Accuracy Studies)-2 tool. Diagnostic accuracy measures were pooled using the random-effects model. Subgroup analysis was conducted by UBT type (13C vs14C) and by measurement technique (Infrared spectrometry vs Isotope Ratio Mass Spectrometry). RESULTS: Out of 1380 studies identified, only 23 met the eligibility criteria. Fourteen studies (61%) evaluated 13C UBT and 9 studies (39%) evaluated 14C UBT. There was significant variation in the type of reference standard tests used across studies.Pooled sensitivity was 0.96 (95%CI: 0.95-0.97) andpooled specificity was 0.93 (95%CI: 0.91-0.94). Likelihood ratio for a positive test was 12 and for a negative test was 0.05 with an area under thecurve of 0.985. Meta-analyses were associated with a significant statistical heterogeneity that remained unexplained after subgroup analysis. The included studies had a moderate risk of bias. CONCLUSION: UBT has high diagnostic accuracy for detecting H. pylori infection in patients with dyspepsia. The reliability of diagnostic meta-analytic estimates however is limited by significant heterogeneity.